SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Amendment #5
Under the Securities Exchange Act of 1934
IMMULOGIC PHARMACEUTICAL CORPORATION
------------------------------------
(Name of Issuer)
Common Stock par value $.01 per share
- ---------------------------------------------------------------------------
(Title of Class of Securities)
45252R 10 0
-----------------
(CUSIP Number)
William K. Hoskins, Esq. Harry R. Benz
General Counsel Hoechst Corporation
Hoechst Marion Roussel, Inc. Route 202-206
9300 Ward Parkway P.O. Box 2500
Kansas City, Missouri 64114 Somerville, NJ 08876-1258
(816) 966-4000 (517) 636-1000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 7, 1996
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(4)(i)(A) or (B), check the
following box. [ ]
Check the following box if a fee is being paid with this statement [ ].
Page 1 of 6
There is no Exhibit Index
<PAGE> 2
CUSIP No. 45252R 10 0
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Marion Roussel, Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ x]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds WC
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 1,250,000*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 1,250,000*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 1,250,000*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 6.29%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Includes 250,000 shares that may be acquired on or before December 17,
1996, upon exercise of a stock option.
<PAGE> 3
CUSIP No. 45252R 10 0
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Corporation
I.R.S. Identification Number 22-1862783
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ X ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not Applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 1,250,000*#
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 1,250,000*#
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 1,250,000*#
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 6.29%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Includes 250,000 shares that may be acquired on or before December 17,
1996, upon exercise of a stock option.
# Hoechst Corporation disclaims beneficial ownership of these securities
(See Item 2 (a) - (c), (f)).
<PAGE> 4
This Amendment to the Statement on Schedule 13D (the "Schedule 13D")
with respect to the Common Stock of ImmuLogic Pharmaceutical Corporation
(the "Issuer"), of Hoechst Marion Roussel, Inc., a Delaware corporation
("HMRI", formerly Marion Merrell Dow Inc. ("MMD")), and Hoechst
Corporation, a Delaware corporation ("Parent"), is filed to reflect changes
in HMRI's business relationship with the Issuer and in HMRI's intention
with respect to its beneficial ownership of securities of the Issuer.
This Statement on Schedule 13D is hereby amended as follows:
ITEM 4. PURPOSE OF TRANSACTION
- ------- ----------------------
Item 4 is hereby amended by adding the following paragraph at the end
thereof:
Notwithstanding the foregoing, after March 7, 1996, HMRI no longer
holds the Shares or the Option for investment purposes and, accordingly,
has decided to sell some or all of the Shares from time to time in the open
market, as and when it appears favorable to HMRI to do so. The timing and
volume of any sales of the Shares will depend on the market price for the
Common Stock and other market conditions at any particular time, as well as
HMRI's evaluation of the Issuer's business, prospects, and financial
condition, other opportunities available to HMRI, prospects for HMRI's own
business, general economic conditions, money and stock market conditions,
and other factors and developments.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS, OR RELATIONSHIPS WITH
- ------- --------------------------------------------------------------
RESPECT TO SECURITIES OF THE ISSUER.
------------------------------------
Item 6 is hereby amended by adding the following paragraph at the end
thereof:
Notwithstanding the foregoing, pursuant to its terms the Collaboration
Agreement has been terminated, effective September 7, 1996.
<PAGE> 5
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
HOECHST MARION ROUSSEL, INC.
Date: March 11, 1996 By: /s/ Rebecca R. Tilden
Rebecca R. Tilden
Vice President, Assistant
General Counsel, and
Assistant Secretary
<PAGE> 6
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
HOECHST CORPORATION
Date: March 11, 1996 By: /s/ David A. Jenkins
David A. Jenkins
Vice president, General
Counsel and Secretary
